Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Feb 15

PMID 35163838

Authors

Bin Bin Wu

Kam Tong Leung

Ellen Ngar-Yun Poon

Affiliations

Soon will be listed here.

Abstract

Anthracyclines, such as doxorubicin, are effective chemotherapeutic agents for the treatment of cancer, but their clinical use is associated with severe and potentially life-threatening cardiotoxicity. Despite decades of research, treatment options remain limited. The mitochondria is commonly considered to be the main target of doxorubicin and mitochondrial dysfunction is the hallmark of doxorubicin-induced cardiotoxicity. Here, we review the pathogenic mechanisms of doxorubicin-induced cardiotoxicity and present an update on cardioprotective strategies for this disorder. Specifically, we focus on strategies that can protect the mitochondria and cover different therapeutic modalities encompassing small molecules, post-transcriptional regulators, and mitochondrial transfer. We also discuss the shortcomings of existing models of doxorubicin-induced cardiotoxicity and explore advances in the use of human pluripotent stem cell derived cardiomyocytes as a platform to facilitate the identification of novel treatments against this disorder.

Citing Articles

Glucose Metabolism and Tumor Microenvironment: Mechanistic Insights and Therapeutic Implications.

Andryszkiewicz W, Gasiorowska J, Kubler M, Kublinska K, Palkiewicz A, Wiatkowski A Int J Mol Sci. 2025; 26(5).

PMID: 40076506 PMC: 11900028. DOI: 10.3390/ijms26051879.

NADPH Oxidases in Cancer Therapy-Induced Cardiotoxicity: Mechanisms and Therapeutic Approaches.

Adhab A, Altalbawy F, Mahdi M, Baldaniya L, Omar T, Ganesan S Cardiovasc Toxicol. 2025; 25(4):631-649.

PMID: 39966326 DOI: 10.1007/s12012-025-09976-4.

Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease.

Mao Y, Chen H, Zhu W, Ni S, Luo S, Tang S J Inflamm Res. 2025; 18:883-894.

PMID: 39867947 PMC: 11760270. DOI: 10.2147/JIR.S498340.

Edaravone is a Therapeutic Candidate for Doxorubicin-Induced Cardiomyopathy by Activating the Nrf2 Pathway.

Yoshikawa N, Hirata N, Kurone Y, Shimoeda S Pharmacol Res Perspect. 2025; 13(1):e70066.

PMID: 39865410 PMC: 11761446. DOI: 10.1002/prp2.70066.

GV1001, hTERT Peptide Fragment, Prevents Doxorubicin-Induced Endothelial-to-Mesenchymal Transition in Human Endothelial Cells and Atherosclerosis in Mice.

Chen W, Kim S, Kim S, Beheshtian C, Kim N, Shin K Cells. 2025; 14(2).

PMID: 39851526 PMC: 11763685. DOI: 10.3390/cells14020098.

References

Poon E, Yan B, Zhang S, Rushing S, Keung W, Ren L . Transcriptome-guided functional analyses reveal novel biological properties and regulatory hierarchy of human embryonic stem cell-derived ventricular cardiomyocytes crucial for maturation. PLoS One. 2013; 8(10):e77784. PMC: 3804624. DOI: 10.1371/journal.pone.0077784. View

Capranico G, Tinelli S, Austin C, Fisher M, Zunino F . Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta. 1992; 1132(1):43-8. DOI: 10.1016/0167-4781(92)90050-a. View

Khanna A, Pequeno P, Gupta S, Thavendiranathan P, Lee D, Abdel-Qadir H . Increased Risk of All Cardiovascular Disease Subtypes Among Childhood Cancer Survivors: Population-Based Matched Cohort Study. Circulation. 2019; 140(12):1041-1043. DOI: 10.1161/CIRCULATIONAHA.119.041403. View

Pecoraro M, Pala B, Di Marcantonio M, Muraro R, Marzocco S, Pinto A . Doxorubicin‑induced oxidative and nitrosative stress: Mitochondrial connexin 43 is at the crossroads. Int J Mol Med. 2020; 46(3):1197-1209. PMC: 7388829. DOI: 10.3892/ijmm.2020.4669. View

Ruan Y, Dong C, Patel J, Duan C, Wang X, Wu X . SIRT1 suppresses doxorubicin-induced cardiotoxicity by regulating the oxidative stress and p38MAPK pathways. Cell Physiol Biochem. 2015; 35(3):1116-24. DOI: 10.1159/000373937. View

Murabito A, Hirsch E, Ghigo A . Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?. Front Cardiovasc Med. 2020; 7:35. PMC: 7080657. DOI: 10.3389/fcvm.2020.00035. View

Coelho A, Martins T, Couto R, Deus C, Pereira C, Simoes R . Berberine-induced cardioprotection and Sirt3 modulation in doxorubicin-treated H9c2 cardiomyoblasts. Biochim Biophys Acta Mol Basis Dis. 2017; 1863(11):2904-2923. DOI: 10.1016/j.bbadis.2017.07.030. View

Wu Y, Zhang L, Wu Z, Shan T, Xiong C . Berberine Ameliorates Doxorubicin-Induced Cardiotoxicity via a SIRT1/p66Shc-Mediated Pathway. Oxid Med Cell Longev. 2019; 2019:2150394. PMC: 6918936. DOI: 10.1155/2019/2150394. View

Liang X, Wang S, Wang L, Ceylan A, Ren J, Zhang Y . Mitophagy inhibitor liensinine suppresses doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated maladaptive mitochondrial fission. Pharmacol Res. 2020; 157:104846. DOI: 10.1016/j.phrs.2020.104846. View

10.

Maillet A, Tan K, Chai X, Sadananda S, Mehta A, Ooi J . Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. Sci Rep. 2016; 6:25333. PMC: 4855185. DOI: 10.1038/srep25333. View

11.

Kang Y, Chen Y, Epstein P . Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem. 1996; 271(21):12610-6. DOI: 10.1074/jbc.271.21.12610. View

12.

Montalvo R, Doerr V, Min K, Szeto H, Smuder A . Doxorubicin-induced oxidative stress differentially regulates proteolytic signaling in cardiac and skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2019; 318(2):R227-R233. DOI: 10.1152/ajpregu.00299.2019. View

13.

Zhang Y, Yu Z, Jiang D, Liang X, Liao S, Zhang Z . iPSC-MSCs with High Intrinsic MIRO1 and Sensitivity to TNF-α Yield Efficacious Mitochondrial Transfer to Rescue Anthracycline-Induced Cardiomyopathy. Stem Cell Reports. 2016; 7(4):749-763. PMC: 5063626. DOI: 10.1016/j.stemcr.2016.08.009. View

14.

Gebert N, Ryan M, Pfanner N, Wiedemann N, Stojanovski D . Mitochondrial protein import machineries and lipids: a functional connection. Biochim Biophys Acta. 2010; 1808(3):1002-11. DOI: 10.1016/j.bbamem.2010.08.003. View

15.

Kho C, Lee A, Hajjar R . Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy. Nat Rev Cardiol. 2012; 9(12):717-33. PMC: 3651893. DOI: 10.1038/nrcardio.2012.145. View

16.

Karbassi E, Fenix A, Marchiano S, Muraoka N, Nakamura K, Yang X . Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat Rev Cardiol. 2020; 17(6):341-359. PMC: 7239749. DOI: 10.1038/s41569-019-0331-x. View

17.

Lefrak E, Pitha J, ROSENHEIM S, Gottlieb J . A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973; 32(2):302-14. DOI: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2. View

18.

Jing X, Yang J, Jiang L, Chen J, Wang H . MicroRNA-29b Regulates the Mitochondria-Dependent Apoptotic Pathway by Targeting Bax in Doxorubicin Cardiotoxicity. Cell Physiol Biochem. 2018; 48(2):692-704. DOI: 10.1159/000491896. View

19.

Gao J, Xiong Y, Ho Y, Liu X, Chua C, Xu X . Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity. Biochim Biophys Acta. 2008; 1783(10):2020-9. PMC: 2629733. DOI: 10.1016/j.bbamcr.2008.05.027. View

20.

Eilers M, Endo T, Schatz G . Adriamycin, a drug interacting with acidic phospholipids, blocks import of precursor proteins by isolated yeast mitochondria. J Biol Chem. 1989; 264(5):2945-50. View